News Medical on MSN7 小时
Novel multi-biomarker approach enhances chronic kidney disease risk assessment
Prior efforts to identify novel kidney biomarkers as risk factors for chronic kidney disease (CKD) progression have typically ...
PipelineReview.com3 小时
Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy ...
CAMBRIDGE, MA, USA I6, 2024 I Biogen Inc. (Nasdaq: BIIB) – today presented complete results from the Phase 2 IGNAZ study evaluating felzartamab, an ...
News Medical on MSN7 小时
New trial shows felzartamab reduces proteinuria in IgA nephropathy patients
IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their surface.
Medpage Today on MSN12 小时
Alternative Pathway Inhibition Makes Good in IgA Nephropathy
SAN DIEGO -- There was a clinically meaningful reduction in proteinuria with iptacopan (Fabhalta), and a confirmed clinical ...